This study has 2 phases: Phase 1 (dose escalation) and Phase 2 (dose expansion).
The goal of Phase 1 of this clinical research study is to find the highest tolerable dose
combination of selumetinib and olaparib that can be given to patients who have solid tumors
that are advanced or recurrent (has returned after treatment).
The goal of Phase 2 is to learn if the highest tolerable dose combination found in Phase 1
can help to control advanced or recurrent solid tumors.
The safety of the study drug combination will also be studied in both parts.
This is an investigational study. Selumetinib is not FDA approved or commercially available.
It is currently being used for research purposes only. Olaparib is FDA approved and
commercially available for the treatment of ovarian cancer that has a certain type of genetic
mutation (change). It is considered investigational to use selumetinib in combination with
olaparib to treat advanced or recurrent cancer.
The study doctor can explain how the study drugs are designed to work. Up to 90 participants
will be enrolled in this study. All will take part at MD Anderson.